Download Champions' latest AACR 2025 Poster

 Investigating the efficacy of 177-Lu therapeutics in a series of Castrate Resistant Prostate Cancer PDX Models 

One of the major limitations in translational oncology research is the inability to replicate the mutational complexity and etiological diversity observed in patient tumors. Mutational signatures—distinct patterns of DNA alterations—can offer insights into underlying mutagenic processes and DNA repair deficiencies, serving as potential biomarkers for cancer origin and treatment response.

Champions Oncology applied radiopharmaceutical testing to metastatic castration-resistant prostate cancer (mCRPC) PDX models to evaluate the efficacy of 177-Lu therapeutics, incorporating RNA-seq, proteomics, and advanced imaging platforms to create a comprehensive preclinical pipeline.

• PSMA expression profiling via RNA-seq, proteomics, and IHC revealed variable PSMA levels across PDX models, mirroring clinical heterogeneity and reinforcing their biological relevance for patient stratification and therapeutic targeting.

•  Robust workflows integrating radiochemistry, dosimetry, biodistribution, and efficacy testing enabled preclinical models to closely reflect clinical responses, demonstrating that PDX models significantly enhance translatability in radiopharmaceutical development.

• These findings support a comprehensive, end-to-end translational strategy for radiopharmaceuticals that combines biomarker-driven patient selection with advanced imaging and molecular profiling, thereby accelerating the development of personalized radionuclide therapies.